Tech Edge hosted a fireside chat on April 29 at RSAC 2025 in San Francisco with Corey Still, Vice President of Strategic Alliances at Corero Network Security. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed which...

By Daniella Parra Vinson & Elkins represented Sunoco LP (NYSE: SUN) in a definitive agreement with Parkland Corp. (TSX: PKI) where Sunoco will acquire all outstanding shares of Parkland in a cash and equity transaction valued at approximately $9.1 billion,...

Tech Edge hosted a fireside chat on April 30 at Sysdig headquarters in San Francisco with Karen Walker, Chief Financial Officer. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed the market trends driving increased investment in...

Tech Edge hosted a fireside chat on April 29 at RSAC 2025 in San Francisco with Seth Spergel, Managing Partner at Merlin Ventures. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed why Merlin Ventures has focused...

By Karen Roman Recordati said it established its three-year financial targets for 2025-2027, with expected revenue of €3.0 to €3.2 billion for 2027 and EBITDA of €1.14 to €1.225 billion. The company’s strategy is driven by organic growth, its leadership,...

By Daniella Parra Araris Biotech AG  joined a research agreement with Johnson & Johnson’s Janssen Biotech to advance the development of next-generation antibody-drug conjugates (ADCs), they said. The partnership will leverage Araris’ proprietary AraLinQ technology, a one-step, enzymatic conjugation platform...

By Karen Roman ReAlta Life Sciences said it is presenting new data from its hypoxic ischemic encephalopathy (HIE) program at the Pediatric Academic Societies Annual Meeting, taking place in Honolulu, Hawaii, from April 24-28, 2025. The findings confirm elevated inflammatory...

Tech Edge hosted a fireside chat on April 22 at Nasdaq MarketSite with Jason Matuszewski, Chief Executive Officer of BioStem Technologies, Inc. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed why the company’s 2024 revenue surged 18x,...

By Karen Roman March Biosciences said it started Phase 2 trial for MB-105, its CAR-T therapy for patients with relapsed or refractory CD5+ T-cell lymphoma. The test will take place at leading cancer centers across the country, with the first...

By Karen Roman Ascentage Pharma Group Internat (Nasdaq: AAPG) said two of its proprietary drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. The added drugs are lisaftoclax and olverembatinib; the former used to diagnose...